Biogen looks to expand neuro pipeline via C4, Skyhawk deals

A pair of deals announced Friday leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen entered R&D partnerships with targeted protein degradation company C4 Therapeutics Inc. (Cambridge, Mass.) and spliceosome company Skyhawk Therapeutics Inc. (Waltham, Mass.).

Skyhawk uses its SkySTAR platform to develop small molecules capable of modulating RNA splicing within the spliceosome, while C4T uses its Degronimid platform to find small molecules that induce proteasomal degradation of disease-associated proteins by tethering them to ubiquitin (see "Splice Time"; "Degradation by Degronimid")...